Looks like approval might come earlier than we thought.
Here is a recent article which estimated time from BTD to approval at four months.
However, I did the math, using data published on the FDA web site (FDA) as well as press released from individual Pharma companies re BTD announcements. I found that the average days to market was 235, or roughly 8.8 months. That would suggest an AP26113 approval date somewhere around July (my estimate in a prior post was August, so not much as changed). However, as I noted previously, the approval can be as fast as 55 days (Amgen's Blincyto), or as long as 498 days (Merck's Keytruda)
Hang in there everyone.
No comments:
Post a Comment
Comments?